Sanger spinout gets $10M to work on live bacteriotherapies

Microbiotica is working to take potentially therapeutic mixes of bacteria into preclinical development.

A spinout from the Wellcome Trust Sanger Institute’s microbiome research group has raised $10 million to advance live bacteriotherapy programs. The startup, Microbiotica, is helmed by a former GlaxoSmithKline executive and built on years of work to sequence the genomes of the thousands of bacteria that inhabit the guts of humans.

Trevor Lawley’s lab at Sanger Institute has established itself at the forefront of microbiome research on the strength of its role in the Human Pan-Microbe Communities database and growth of bacteria previously thought to be impossible to culture. The initiatives have enabled the lab to build a sizable collection of gut bacteria—including 90 the Human Microbiome Project put on its “most wanted” list in 2012—and humanized models to support the development of drugs based on live bacteria.

Now, Lawley wants to use these resources and expertise to develop live bacteriotherapy programs at Microbiotica. Lawley has taken on the CSO role at the spinout. And Mike Romanos has come on board as CEO. Romanos is the former CEO of Crescendo Biologics, a post he took up in 2011 after a stint helping GSK to establish its antibody operation.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

The combination of the Sanger Institute’s science and the leadership team in place to advance it proved compelling enough to prompt IP Group and Cambridge Innovation Capital to commit approximately $5 million each to the startup. Microbiotica plans to use the cash to set up digs at the Wellcome Genome Campus near Cambridge, U.K., from which it will work to take multiple live bacteriotherapy programs into development.

Microbiotica’s near-term focus is on getting potentially therapeutic mixes of bacteria identified by Lawley’s lab into preclinical development. In parallel, Microbiotica will tap into resources accrued by the Sanger Institute to understand the microbiomes of healthy and diseased people. The work is expected to identify links between bacteria and disease, ways to stratify patients and therapeutic candidates.

“By exploring the fundamentals of gut flora distribution and genetics, Microbiotica has an opportunity to take a lead in understanding how the microbiome can be used to not only develop new therapeutics for a range of diseases, but also how to stratify patients according to their microbial profile, identify links with disease and exploit its full potential for human healthcare,” Sam Williams, head of biotech at IP Group, said in a statement.


Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.